MetaVia doses first patient in Part 3 of DA-1726 obesity trial
Share
MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company focused on metabolic diseases, announced on April 10, 2026, that it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726.
